Alumis (ALMS) Income from Non-Controlling Interests (2023 - 2025)
Alumis' (ALMS) quarterly Income from Non-Controlling Interests came in at -$46000.0 in Q4 2025, up 53.54% year-on-year from -$29960.5 in Q4 2024, and down 121.7% on a QoQ basis from $212000.0 in Q3 2025.
Alumis (ALMS) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$46000.0 in Q4 2025.
- On a quarterly basis, Income from Non-Controlling Interests rose 53.54% year-over-year to -$46000.0 in Q4 2025; TTM through Dec 2025 was $148000.0, a 289.47% increase from a year earlier, with the FY2025 full-year figure at $148000.0, up 289.47% from the prior year.
- Income from Non-Controlling Interests for Q4 2025 stood at -$46000.0, down from $212000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for ALMS reached as high as $212000.0 in Q3 2025 and fell as low as -$99000.0 in Q4 2024.
- Historically, Income from Non-Controlling Interests has averaged $21500.0 across 3 years, with a median of -$500.0 in 2023.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 4766.67% in 2024 and fell as far as 5050.0% in 2024.
- Year by year, Income from Non-Controlling Interests stood at $2000.0 in 2023, then plunged by 5050.0% to -$99000.0 in 2024, then surged by 53.54% to -$46000.0 in 2025.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$46000.0 in Q4 2025, $212000.0 in Q3 2025, and $30000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | - |
| 10 | Alumis | 2.36 Bn | 2.05 Bn | - | -46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46,000.00 |
| Sep 30, 2025 | 212,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | -48,000.00 |
| Dec 31, 2024 | -99,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Mar 31, 2024 | -3,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Sep 30, 2023 | -3,000.00 |
| Jun 30, 2023 | 30,000.00 |